Search

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more

Leading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day

“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.

Read more

Chairs and Members

Chair
Edward Laane, Tartu University, Estonia (2022–2024)
Vice-Chair
Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy (2022–2024)
Sam Salek, University of Hertfordshire, United Kingdom (2022–2024)
Steering Committee
Tatiana Ionova, St.

Read more

Committees and units

The EHA Board sets up committees and units to perform specific tasks and activities.

Read more